Invest in the future of non-surgical cancer treatment
Non-Invasive Thermal Ablation Technology addressing an unmet need in the treatment of solid superficial tumors.
Learn More, Invest Later
Not ready to invest just yet? Watch our video to learn more about our mission or leave your details and we'll keep you updated.
SynergyMed in 2 Minutes
Here directly from our CEO, how SynergyMed is changing cancer treatment without surgery.
Join Our WeFunder Campaign
We are currently raising capital on WeFunder and have secured over $0 toward our $1,235,000 raise, with approximately 80 days remaining in the round.
56% funded
Why Investors Are Excited About SynergyMed
Patented Technology
Protected intellectual property in both the U.S. and Europe
Letters of Intent
Strategic interest from Boston Scientific and Medtronic
Proven Preclinical Results
Complete tumor elimination in mice and dogs after a single, 10-minute non-invasive treatment
Leading Collaborations
Active partnerships with institutions including The Ohio State University
Strong Revenue Potential
Commercialization strategy targeting up to $100M in revenue within five years (subject to market conditions)
Milestones
Our roadmap from prototype to market leadership
Phase 1
- •Build 1 Prototype
- •Mice studies successfully completed
- •Dog studies successfully completed
Phase 3
- •Extended clinical studies on dogs in the US
- •Initiate partnerships with distributors and clinics
Phase 5
- •Continue First in Human Studies
- •Expand veterinary sales by working with strategics
Phase 7
- •Launch sales in the human market
Phase 2
- •Convert Prototype to Product. Ready for clinical studies
- •Built a team and business strategy
Phase 4
- •Perform First in Human Studies on 5-10 patients
- •Launch veterinary sales
Phase 6
- •Start human clinical trials on 60-80 patients at 3 different sites
- •Submit for FDA approval
Phase 8
- •Grow sales for human market
- •Build 1 Prototype
- •Mice studies successfully completed
- •Dog studies successfully completed
- •Convert Prototype to Product. Ready for clinical studies
- •Built a team and business strategy
- •Extended clinical studies on dogs in the US
- •Initiate partnerships with distributors and clinics
- •Perform First in Human Studies on 5-10 patients
- •Launch veterinary sales
- •Continue First in Human Studies
- •Expand veterinary sales by working with strategics
- •Start human clinical trials on 60-80 patients at 3 different sites
- •Submit for FDA approval
- •Launch sales in the human market
- •Grow sales for human market
Executive Team
Experienced from leading corporate and academic institutions
Anan Copty, Ph.D.
Founder & CEO
25+ years of technical & leadership experiences, RMD: Radiation Monitoring Devices, Intel: Biochips
Daniel Kacher, Ph.D.
Director of Clinical Studies
Ph.D. in Biomedical Engineering, 25 years at Brigham and Women's Hospital
Robert Roy, MBA
VP of Marketing, Sales
35+ years of senior-level management in medical device companies
Advisors
Expert guidance from world-class medical professionals
Pre-Clinical
Why They Believe in Us
Join hundreds of investors who are helping us bring non-invasive cancer treatment to the world.
Robert
Fairfield, CA
Myron
Oak Island, NC
Diana B.
Owner, Animal and Environment Association